Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Related Citations for PubMed (Select 22329523)

1.

Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors.

Chinello P, Cicalini S, Pichini S, Pacifici R, Tempestilli M, Petrosillo N.

Curr HIV Res. 2012 Mar;10(2):162-4.

PMID:
22329523
2.

Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors.

Aschmann YZ, Kummer O, Linka A, Wenk M, Azzola A, Bodmer M, Krähenbühl S, Haschke M.

Ther Drug Monit. 2008 Feb;30(1):130-4. doi: 10.1097/FTD.0b013e318165ba71.

PMID:
18223477
3.

Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.

Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans RM.

Clin Drug Investig. 2008;28(8):479-85.

PMID:
18598093
4.

Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.

Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, Mulcahy F, Back DJ.

AIDS. 1999 Oct 22;13(15):F101-7.

PMID:
10546851
5.

Sildenafil does not alter nelfinavir pharmacokinetics.

Bratt G, Ståhle L.

Ther Drug Monit. 2003 Apr;25(2):240-2.

PMID:
12657921
6.

A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension.

Satoh T, Saji T, Watanabe H, Ogawa S, Takehara K, Tanabe N, Yamada N, Yao A, Miyaji K, Nakanishi N, Suzuki Y, Fujiwara T, Kuriyama T.

Circ J. 2011;75(3):677-82. Epub 2011 Feb 4. Erratum in: Circ J. 2011 Jul;75(7):1779. Satoh, Tohru [corrected to Satoh, Toru].

7.

Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.

Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N.

Br J Clin Pharmacol. 2000 Aug;50(2):99-107.

8.
9.

The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.

Xu XQ, Jing ZC, Zhang JH, Wu Y, Wang Y, Jiang X, Wang ZX, Sun YG, Pu JL, Yang YJ.

Hypertens Res. 2009 Oct;32(10):911-5. doi: 10.1038/hr.2009.113. Epub 2009 Jul 31.

PMID:
19644505
10.

Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.

Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA.

Pulm Pharmacol Ther. 2008 Oct;21(5):824-32. doi: 10.1016/j.pupt.2008.07.003. Epub 2008 Jul 9.

PMID:
18657627
11.

Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension.

Apitz C, Reyes JT, Holtby H, Humpl T, Redington AN.

J Am Coll Cardiol. 2010 Apr 6;55(14):1456-62. doi: 10.1016/j.jacc.2009.11.065.

12.

Simultaneous assay of sildenafil and desmethylsildenafil in neonatal plasma by ultra-performance liquid chromatography-tandem mass spectrometry.

Witjes BC, Ahsman MJ, van der Nagel BC, Tibboel D, Mathot RA.

Biomed Chromatogr. 2010 Feb;24(2):180-5. doi: 10.1002/bmc.1268.

PMID:
19609867
13.
14.

Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

Kasserra C, O'Mara E.

Clin Pharmacokinet. 2011 Apr;50(4):267-80. doi: 10.2165/11584560-000000000-00000.

PMID:
21348539
15.

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.

Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group.

Chest. 2011 Nov;140(5):1274-83. doi: 10.1378/chest.10-0969. Epub 2011 May 5.

PMID:
21546436
16.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; SPIRAL Study Group.

AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a. Erratum in: AIDS. 2010 Oct 23;24(16):2602.

PMID:
20467288
17.

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).

Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, Johnson M, Meier U, MacGregor TR, Leith JG.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):429-40. doi: 10.1097/QAI.0b013e318160a529.

PMID:
18176328
18.

Sildenafil: a review of its use in pulmonary arterial hypertension.

Croom KF, Curran MP.

Drugs. 2008;68(3):383-97. Review.

PMID:
18257613
19.

Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.

PMID:
18022071
20.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk